[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD: A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs; 2008 Aug;26(4):369-79
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
  • Therefore, the Phase 2 Consortium (P2C) initiated a trial (two single stage studies with planned interim analysis) of 3-AP at 96 mg/m(2) intravenously days 1-4 and 15-18 of a 28-day cycle in both chemotherapy-naive and gemcitabine-refractory (GR) patients with advanced pancreatic cancer.
  • The primary endpoint was survival at six months (chemotherapy-naive) and four months (GR).
  • Secondary endpoints were toxicity, response, overall survival, time to progression and mechanistic studies.
  • Fifteen patients were enrolled including one chemotherapy-naïve and 14 GR.
  • The chemotherapy-naïve patient progressed during cycle 1 with grade 3 and 4 toxicities.
  • Progression precluded further treatment in 11 GR patients.
  • Additionally, one died of an ileus in cycle 1 considered related to treatment and two stopped treatment due to toxicity.
  • Correlative studies confirmed that 3-AP increased the percentage of S-phase buccal mucosal cells, the presence of multidrug resistance gene polymorphisms appeared to predict leukopenia, and baseline pancreatic tumor RR M2 expression was low relative to other tumors treated with 3-AP.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278438.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CM / N01 CM062205; United States / NCI NIH HHS / CM / N01 CM-62205; United States / PHS HHS / / 1ULIRR025011; United States / NCRR NIH HHS / RR / UL1 RR025011; United States / NCI NIH HHS / CA / T32 CA009614; United States / PHS HHS / / 24XS090
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyridines; 0 / Thiosemicarbazones; 0W860991D6 / Deoxycytidine; 143621-35-6 / 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / ribonucleotide reductase M2; EC 1.17.4.1 / Ribonucleoside Diphosphate Reductase
  • [Other-IDs] NLM/ NIHMS692508; NLM/ PMC4461052
  •  go-up   go-down


2. Uematsu T, Hasegawa T, Hiraoka BY, Komatsu F, Matsuura T, Yamada AS, Yamaoka M: Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer; 2001 Apr 15;92(2):187-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas.
  • In combined chemotherapy for head-and-neck cancer (HNC), salivary gland-cell adenocarcinoma (SGA) shows insufficient clinical outcome, and it has been suggested that the sensitivity and/or the mechanism of resistance to anti-cancer drugs are different between SGA and oral squamous-cell carcinoma (SCC).
  • In immunohistochemical analysis, P-gp expression was found in the ductal cells of salivary glands but not in oral mucosal epithelium.
  • In cancer tissues, a few SCC cells in 12 of 37 and most cells in all SGAs expressed P-gp.
  • However, P-gp expression was developed in both HSY and Hepd cell lines after vincristine (VCR) treatment.
  • RT-PCR showed that the mean ratios of mdr1 mRNA expression levels in HSY clones were 3.7-fold higher than those in Hepd clones after VCR treatment, while each cell line exhibited both induction and activated production of P-gp.
  • These results suggest that P-gp-related MDR in SGA is an inherent phenotype caused by both high levels of P-gp induction and activated P-gp production during VCR treatment, while that in SCC is an acquired phenotype chiefly caused by induction of P-gp.
  • [MeSH-major] Adenocarcinoma / genetics. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / genetics. Drug Resistance, Neoplasm. Genes, MDR. Mouth Neoplasms / genetics. Salivary Gland Neoplasms / genetics. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Aged. Animals. Cell Division / drug effects. Cell Survival / drug effects. Drug Resistance, Multiple. Female. Gene Expression Regulation, Neoplastic. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / metabolism. Humans. Male. Mice. Mice, Nude. Middle Aged. P-Glycoprotein / biosynthesis. RNA, Messenger / biosynthesis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11291044.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / P-Glycoprotein; 0 / RNA, Messenger; 5J49Q6B70F / Vincristine
  •  go-up   go-down


3. Check JH, Dix E, Sansoucie L, Check D: Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report. Anticancer Res; 2009 May;29(5):1611-3
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report.
  • MATERIALS AND METHODS: Mifepristone 200 mg per day by mouth was given to two patients with stage 4 colon cancer with extensive metastases.
  • Though the metastatic lesions did not disappear, no new ones appeared for a long time and the ones present did not grow.
  • The drug was extremely well tolerated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy. Mifepristone / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443374.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 320T6RNW1F / Mifepristone
  •  go-up   go-down


Advertisement
4. Bayani N, Rugina M, Haddad-Vergnes L, Lelong F: High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. Am J Hematol; 2002 Sep;71(1):33-6
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 79-year-old man with two simultaneous malignant tumors (buccal epidermoid carcinoma and prostatic adenocarcinoma) who developed a severe bleeding complication at the site of the buccal tumor as well as a massive cerebral hematoma after a skull trauma.
  • The patient failed to respond to intravenous immunoglobulins, but both clinical and laboratory improvement was obtained after treatment with corticosteroids and cyclophosphamide.
  • [MeSH-major] Adenocarcinoma / immunology. Autoantibodies / biosynthesis. Autoimmune Diseases / etiology. Carcinoma, Squamous Cell / immunology. Cyclophosphamide / therapeutic use. Factor V / immunology. Hemorrhage / etiology. Immunosuppressive Agents / therapeutic use. Mouth Neoplasms / immunology. Neoplasms, Multiple Primary / immunology. Prednisone / therapeutic use. Prostatic Neoplasms / immunology
  • [MeSH-minor] Aged. Cerebral Hemorrhage / etiology. Craniocerebral Trauma / complications. Drug Therapy, Combination. Humans. Immunoglobulins, Intravenous / therapeutic use. Male

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12221671.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Immunoglobulins, Intravenous; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; 9001-24-5 / Factor V; VB0R961HZT / Prednisone
  •  go-up   go-down


5. Kariya S, Kosaka M, Orita Y, Akagi H, Nishizaki K: Adenocarcinoma ex pleomorphic adenoma of the head and neck: Report of five cases. Auris Nasus Larynx; 2006 Mar;33(1):43-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma ex pleomorphic adenoma of the head and neck: Report of five cases.
  • OBJECTIVE: Adenocarcinoma ex pleomorphic adenoma is a rare tumor, and thus the management of the tumor has not been established.
  • RESULTS: We present five cases of adenocarcinoma ex pleomorphic adenoma of the head and neck, including a rare case with nasopharyngeal adenocarcinoma ex pleomorphic adenoma.
  • There was no response to chemotherapy with nedaplatin and 5-FU, but the nasopharyngeal adenocarcinoma ex pleomorphic adenoma showed a remarkable regression after the administration of docetaxel.
  • CONCLUSION: The combination therapy that includes docetaxel may be a promising treatment for adenocarcinoma ex pleomorphic adenoma of the head and neck.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Mouth Neoplasms / pathology. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Organoplatinum Compounds / administration & dosage. Palate / pathology. Parotid Gland / pathology. Retrospective Studies. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168590.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. King M, Chatelain K, Farris D, Jensen D, Pickup J, Swapp A, O'Malley S, Kingsley K: Oral squamous cell carcinoma proliferative phenotype is modulated by proanthocyanidins: a potential prevention and treatment alternative for oral cancer. BMC Complement Altern Med; 2007;7:22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral squamous cell carcinoma proliferative phenotype is modulated by proanthocyanidins: a potential prevention and treatment alternative for oral cancer.
  • BACKGROUND: Despite the recently reported drop in the overall death rate from cancer, the estimated survival rate and number of deaths from oral cancer remain virtually unchanged.
  • Early detection efforts, in combination with strategies for prevention and risk-reduction, have the potential to dramatically improve clinical outcomes.
  • The identification of non-toxic, effective treatments, including complementary and alternative therapies, is critical if the survival rate is to be improved.
  • The primary purpose of this study was to investigate the response of human oral squamous cell carcinoma (OSCC) to proanthocyanidin (PAC), a plant-derived compound that may inhibit the progression of several other cancers.
  • Our results also provide preliminary evidence that PAC administration may induce apoptosis in cervical and oral cancer cell lines, while acting merely to suppress proliferation of the normal cell line control.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Proanthocyanidins / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Female. Fibroblasts / drug effects. Human papillomavirus 16. Humans. Papillomavirus Infections / drug therapy. Phenotype. Uterine Cervical Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):271-7 [10769666.001]
  • [Cites] J Dent Res. 2007 Feb;86(2):104-14 [17251508.001]
  • [Cites] Toxicology. 2000 Aug 7;148(2-3):187-97 [10962138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10544-8 [10962037.001]
  • [Cites] J Agric Food Chem. 2000 Nov;48(11):5331-7 [11087482.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun;91(6):622-35 [11402272.001]
  • [Cites] Free Radic Res. 2001 Aug;35(2):181-94 [11697199.001]
  • [Cites] J Agric Food Chem. 2002 Feb 27;50(5):1063-9 [11853481.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 10;293(3):1000-6 [12051759.001]
  • [Cites] Ann N Y Acad Sci. 2002 May;957:260-70 [12074978.001]
  • [Cites] J Agric Food Chem. 2002 Aug 14;50(17):4852-60 [12166971.001]
  • [Cites] Biomed Pharmacother. 2002 Aug;56(6):296-301 [12224601.001]
  • [Cites] Cancer Metastasis Rev. 2002;21(3-4):231-55 [12549763.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1302-16 [12618755.001]
  • [Cites] Mutat Res. 2003 Feb-Mar;523-524:87-97 [12628506.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 May;67(5):1140-3 [12834296.001]
  • [Cites] Biochemistry (Mosc). 2004 Jan;69(1):75-80, 1 p preceding 75 [14972022.001]
  • [Cites] J Nutr. 2004 Mar;134(3):613-7 [14988456.001]
  • [Cites] Oral Oncol. 2004 May;40(5):461-73 [15006617.001]
  • [Cites] J Agric Food Chem. 2004 May 5;52(9):2512-7 [15113149.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):987-95 [14742313.001]
  • [Cites] Thromb Res. 2005;115(1-2):115-21 [15567462.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3445S-3452S [15570052.001]
  • [Cites] Am J Clin Nutr. 2005 Jan;81(1 Suppl):230S-242S [15640486.001]
  • [Cites] Mol Cell Biochem. 2006 Jan;281(1-2):197-209 [16328973.001]
  • [Cites] J Nutr Biochem. 2006 Feb;17(2):117-25 [16111875.001]
  • [Cites] Chin Med J (Engl). 2006 Mar 5;119(5):417-21 [16542587.001]
  • [Cites] Endocr Metab Immune Disord Drug Targets. 2006 Mar;6(1):17-24 [16611161.001]
  • [Cites] Am J Clin Nutr. 2006 May;83(5):1126-34 [16685056.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5960-7 [16740737.001]
  • [Cites] Nutr Cancer. 2006;54(1):58-68 [16800773.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Sep;135(3):451-7 [16949981.001]
  • [Cites] Biofactors. 2006;27(1-4):245-65 [17012779.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6194-202 [17062697.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):186S-193S [17182824.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):423-6 [10769690.001]
  • (PMID = 17578576.001).
  • [ISSN] 1472-6882
  • [Journal-full-title] BMC complementary and alternative medicine
  • [ISO-abbreviation] BMC Complement Altern Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proanthocyanidins
  • [Other-IDs] NLM/ PMC1914364
  •  go-up   go-down


7. Yeh JS, Munn SE, Plunkett TA, Harper PG, Hopster DJ, du Vivier AW: Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol; 2000 Feb;42(2 Pt 2):357-62
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: a case report and literature review.
  • Our patient was a 69-year-old man, who presented with hematemesis; a stage-IV poorly differentiated, diffuse-type, adenocarcinoma of the gastric antrum was diagnosed.
  • The AN was striking, with florid cutaneous papillomatosis that also involved the mucous membranes of the mouth and eyelids, and keratoderma.
  • AN and the sign of LT predated tumor detection by 6 months and regressed after chemotherapy in parallel with reduction of the tumor load, demonstrating the dermatoses as paraneoplastic phenomena.
  • The patient died 7 months after completion of chemotherapy.
  • [MeSH-major] Acanthosis Nigricans / diagnosis. Adenocarcinoma / diagnosis. Keratosis, Seborrheic / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Fatal Outcome. Gastric Mucosa / pathology. Humans. Male. Mouth Mucosa / pathology. Skin / pathology

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10640933.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 50
  •  go-up   go-down


8. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res; 2008 Jul 15;14(14):4491-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Food and Drug Administration-approved therapies for it, gemcitabine and erlotinib, produce objective responses in <10% of patients.
  • EXPERIMENTAL DESIGN: Patients received 8 g curcumin by mouth daily until disease progression, with restaging every 2 months.
  • Circulating curcumin was detectable as drug in glucuronide and sulfate conjugate forms, albeit at low steady-state levels, suggesting poor oral bioavailability.
  • Whereas there was considerable interpatient variation in plasma curcumin levels, drug levels peaked at 22 to 41 ng/mL and remained relatively constant over the first 4 weeks.
  • CONCLUSIONS: Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Curcumin / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclooxygenase 2 / drug effects. Cyclooxygenase 2 / metabolism. Cytokines / blood. Cytokines / drug effects. Electrophoretic Mobility Shift Assay. Female. Humans. Immunohistochemistry. Male. Middle Aged. NF-kappa B / drug effects. NF-kappa B / metabolism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2009 Jan 15;15(2):747; author reply 747 [19147784.001]
  • [CommentIn] Clin Cancer Res. 2009 Nov 15;15(22):7108; author reply 7108-9 [19903776.001]
  • (PMID = 18628464.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA101936; United States / NCI NIH HHS / CA / R21 CA104337
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / NF-kappa B; EC 1.14.99.1 / Cyclooxygenase 2; IT942ZTH98 / Curcumin
  •  go-up   go-down


9. Saif MW, Hashmi S: Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol; 2008 Mar;61(3):349-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Oxaliplatin, a platinum derivative used in the treatment of gastrointestinal cancers, has been associated with sensory neuropathies and, more infrequently, a neuromyotonia-like hyperexcitability syndrome.
  • We present a case of hyperexcitability syndrome that developed during the treatment of pancreatic cancer with oxaliplatin and gemcitabine (GEMOX) that was successfully treated with pregabalin.
  • CASE PRESENTATION: A 54-year-old woman was undergoing chemotherapy with gemcitabine and oxaliplatin (GEMOX) for stage II-B pancreatic adenocarcinoma.
  • In addition to reassurance, pregabalin was prescribed for these myotonic symptoms at a dosage of 50 mg by mouth three times daily.
  • Hyperexcitability syndrome, distinct from cold-induced paresthesias and sensory neuropathy, is a rare complication of oxaliplatin chemotherapy; and up to date no pharmacotherapy has been successful in treating these symptoms.
  • [MeSH-major] Adenocarcinoma / complications. Anticonvulsants / therapeutic use. Antineoplastic Agents / adverse effects. Organoplatinum Compounds / adverse effects. Pancreatic Neoplasms / complications. Psychomotor Agitation / drug therapy. gamma-Aminobutyric Acid / analogs & derivatives
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Calcium Gluconate / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Diphenhydramine / therapeutic use. Female. Histamine H1 Antagonists / therapeutic use. Humans. Magnesium Sulfate / therapeutic use. Pregabalin

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. PREGABALIN .
  • Hazardous Substances Data Bank. CALCIUM GLUCONATE .
  • Hazardous Substances Data Bank. DIPHENHYDRAMINE .
  • Hazardous Substances Data Bank. MAGNESIUM SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17849118.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Histamine H1 Antagonists; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 55JG375S6M / Pregabalin; 56-12-2 / gamma-Aminobutyric Acid; 7487-88-9 / Magnesium Sulfate; 8GTS82S83M / Diphenhydramine; B76N6SBZ8R / gemcitabine; SQE6VB453K / Calcium Gluconate
  •  go-up   go-down


10. Williams C, Collingwood M, Simera I, Grafton C: Short versus long duration infusions of paclitaxel for any adenocarcinoma. Cochrane Database Syst Rev; 2002;(4):CD003911
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short versus long duration infusions of paclitaxel for any adenocarcinoma.
  • BACKGROUND: Paclitaxel has become a standard drug used in a number of common cancers.
  • At first long infusions were used to reduce the rate of inflow of the drug and as a result reduce the occurrence of hypersensitivity types of allergic reactions.
  • Trials with shorter durations of infusion, and using a cocktail of anti-allergic drugs to prevent hypersensitivity reactions, some randomised, were begun.
  • These were interpreted as showing that effectiveness of treatment was not lessened by a short infusion time.
  • SEARCH STRATEGY: Electronic searches of the Cochrane Gynaecological Cancer CRG, the Cochrane Register of Controlled Trials, MEDLINE, EmBase, CANCERLIT, PDQ, Meta-register (mRCT) and the M.D.
  • SELECTION CRITERIA: The review was restricted to randomised controlled trials of single agent paclitaxel or paclitaxel with other drugs, where the only variable was the duration of paclitaxel infusion.
  • The review only included patients with advanced adenocarcinoma.
  • MAIN RESULTS: Three hour paclitaxel infusions appear to result in a smaller fall in white blood cell count, less fever, infection and sore mouth than 24 hour infusions.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12519619.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 9
  •  go-up   go-down


11. Williams C, Collingwood M, Simera I, Grafton C: Short versus long duration infusions of paclitaxel for any adenocarcinoma. Cochrane Database Syst Rev; 2003;(1):CD003911
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short versus long duration infusions of paclitaxel for any adenocarcinoma.
  • BACKGROUND: Paclitaxel has become a standard drug used in a number of common cancers.
  • At first long infusions were used to reduce the rate of inflow of the drug and as a result reduce the occurrence of hypersensitivity types of allergic reactions.
  • Trials with shorter durations of infusion, and using a cocktail of anti-allergic drugs to prevent hypersensitivity reactions, some randomised, were begun.
  • These were interpreted as showing that effectiveness of treatment was not lessened by a short infusion time.
  • SEARCH STRATEGY: Electronic searches of the Cochrane Gynaecological Cancer CRG, the Cochrane Register of Controlled Trials, MEDLINE, EmBase, CANCERLIT, PDQ, Meta-register (mRCT) and the M.D.
  • SELECTION CRITERIA: The review was restricted to randomised controlled trials of single agent paclitaxel or paclitaxel with other drugs, where the only variable was the duration of paclitaxel infusion.
  • The review only included patients with advanced adenocarcinoma.
  • MAIN RESULTS: Three hour paclitaxel infusions appear to result in a smaller fall in white blood cell count, less fever, infection and sore mouth than 24 hour infusions.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Breast Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2011;(5):CD003911 [21563139.001]
  • (PMID = 12535492.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 9
  •  go-up   go-down


12. Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV: Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol; 2003 Jan;14(1):97-104
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
  • BACKGROUND: Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials.
  • Based on this background and in order to define the therapeutic potential and tolerance of this combination more precisely, the present randomized multicenter phase II trial was initiated.
  • PATIENTS AND METHODS: We prospectively randomized 83 patients to treatment with biweekly gemcitabine 2,200 mg/m(2) given as a 30 min intravenous infusion on day 1, or the same treatment plus oral capecitabine 2,500 mg/m(2) given from days 1 to 7.
  • In both arms, chemotherapy was administered for a duration of 6 months unless there was prior evidence of progressive disease.
  • The efficacy of the two treatment arms was evaluated according to standard criteria, i.e. objective response, progression-free survival (PFS) and overall survival (OS), as well as by analysis of clinical benefit response.
  • Chemotherapy was well tolerated in both arms with only four versus six patients experiencing WHO grade 3 symptoms.
  • CONCLUSIONS: Results of this trial suggest a fairly good therapeutic index for the combination of biweekly high-dose gemcitabine and capecitabine for the treatment of advanced pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12488300.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Uji M, Matsushita H, Watanabe T, Suzumura T: [A case of primary Sjögren's syndrome complicated with lung adenocarcinoma]. Nihon Kokyuki Gakkai Zasshi; 2007 May;45(5):409-12
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary Sjögren's syndrome complicated with lung adenocarcinoma].
  • The serum value of carcinoembryonic antigen was highly elevated, so we made a presumed diagnosis of primary non-small lung cancer.
  • She also complained of dry eyes and mouth.
  • The elevated values of serum antibodies against SS-A and SS-B and further examinations resulted in a definitive diagnosis of primary Sjögren's syndrome.
  • Chemotherapy was not effective and she died 14 months later.
  • Autopsy revealed that the mass shadow was a primary lung adenocarcinoma.
  • Thoracic CT scans at that time showed a nodule next to a cystic lesion.
  • [MeSH-major] Adenocarcinoma / complications. Lung Neoplasms / complications. Sjogren's Syndrome / complications

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554985.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G: Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer; 2010;62(8):1137-41
Hazardous Substances Data Bank. CURCUMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventeen patients were enrolled in the study and received 8,000 mg of curcumin by mouth daily, concurrently with gemcitabine 1,000 mg/m(2) IV weekly × 3 of 4 wk; 5 patients (29%) discontinued curcumin after a few days to 2 wk due to intractable abdominal fullness or pain, and the dose of curcumin was reduced to 4,000 mg/day because of abdominal complaints in 2 other patients.
  • Time to tumor progression was 1-12 mo (median 2½), and overall survival was 1-24 mo (median 5).
  • Low compliance for curcumin at a dose of 8,000 mg/day, when taken together with systemic gemcitabine, may prevent the use of high doses of oral curcumin needed to achieve systemic effect.
  • Further studies should be conducted to evaluate the ability of other formulations of curcumin to enhance the effect of chemotherapy in cancer patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Curcumin / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Disease Progression. Feasibility Studies. Female. Humans. Male. Medication Adherence. Middle Aged. Severity of Illness Index. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21058202.001).
  • [ISSN] 1532-7914
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / bisdesmethoxycurcumin; 0 / desmethoxycurcumin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; IT942ZTH98 / Curcumin
  •  go-up   go-down


15. Wong SJ, Sadasiwan C, Erickson B, Ota D, Mulkerin D, Thomas J, Holen K, Meadows S, Telford G, Gore E: A phase II trial of pre-operative capecitabine and concurrent radiation for locally advanced rectal cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):3771

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3771 Background: Concurrent 5-FU-based chemotherapy and radiation therapy (RT) have an established role in the pre-operative management of locally advanced rectal cancer.
  • We sought to examine the efficacy and toxicity of capecitabine, an oral fluoropyrimidine prodrug, with concurrent RT for this disease.
  • Patients with T3, T4, or lymph node (LN) positive adenocarcinoma of the rectum were eligible.
  • RT was administered in 1.8 Gy fractions to a total dose of 50.4 Gy.
  • Capecitabine (1650 mg/m<sup>2</sup>/d) was administered by mouth divided in two daily doses Monday through Friday during the entire course of radiation.
  • Of 8 patients who had primary tumors ≤6 cm from the anal verge, sphincter-preserving therapy was performed in 3 (38%) patients.
  • CONCLUSIONS: Concurrent capecitabine and RT is a well-tolerated, safe, and effective treatment for locally advanced operable rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014136.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ariyoshi Y, Miyatake S, Kimura Y, Shimahara T, Kawabata S, Nagata K, Suzuki M, Maruhashi A, Ono K, Shimahara M: Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep; 2007 Oct;18(4):861-6
Hazardous Substances Data Bank. BORON COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis.
  • The purpose of this clinical trial was to evaluate the utility of boron neutron capture therapy (BNCT) using epithermal neutrons for cases of recurrent cancer in the oral cavity, which are not indicated for a conventional treatment modality.
  • We enrolled four patients with local recurrence or metastasis to the regional lymph nodes after completion of initial treatments, including surgery, chemotherapy and radiotherapy.
  • Before receiving BNCT, patients underwent 18F-p-bononophenylalanine (BPA) positron emission tomography (PET) examinations to assess the BPA accumulation ratios in tumors and normal tissues.
  • Before BNCT, that patient could not be discharged from the hospital because of eating difficulties and malaise; after treatment, he was comfortably discharged.
  • Mild malaise, oral mucositis and alopecia were seen as mild adverse effects; however, no life-threatening systemic symptoms were observed in any of the cases.
  • Our results suggested that BNCT is a useful treatment modality for recurrent or regionally metastasized oral cancer.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Neutrons
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Boron Compounds / therapeutic use. Carcinoma, Mucoepidermoid / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Head and Neck Neoplasms / radiotherapy. Humans. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786347.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Boron Compounds
  •  go-up   go-down


17. Vorob'ev IuI, Garbuzov MM, Retinskaia II, Popov NV: [The clinical picture, diagnosis and radiation treatment principles in cancer of the buccal mucosa]. Stomatologiia (Mosk); 2000;79(1):36-8
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical picture, diagnosis and radiation treatment principles in cancer of the buccal mucosa].
  • Diagnosis and treatment of 228 patients with cancer of the buccal mucosa is analyzed.
  • Adenocarcinoma was diagnosed in 8 (3.5%) and poorly differentiated cancer in 3 patients.
  • For cosmetic reasons, radiotherapy (oral x-ray therapy, interstitial method, long-distance gamma beam therapy) was the method of choice.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma / diagnosis. Carcinoma / radiotherapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / diagnosis. Mouth Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cheek. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Mouth Mucosa. Neoplasm Staging. Radiotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10693346.001).
  • [ISSN] 0039-1735
  • [Journal-full-title] Stomatologii︠a︡
  • [ISO-abbreviation] Stomatologiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] RUSSIA
  •  go-up   go-down


18. Adelson RT, DeFatta RJ, Miles BA, Hoblitt SL, Ducic Y: Metastatic breast cancer of the oral cavity. Am J Otolaryngol; 2005 Jul-Aug;26(4):279-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast cancer of the oral cavity.
  • OBJECTIVE: To present a rare case of breast carcinoma initially presenting as an oral cavity mass.
  • Subsequent investigations revealed widely metastatic disease for which the patient was referred for palliative chemotherapy.
  • CONCLUSIONS: Metastatic disease to the oral cavity represents only 1% of all oral cavity malignancies.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Mouth Neoplasms / secondary
  • [MeSH-minor] Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Female. Humans. Immunohistochemistry. Middle Aged. Palliative Care. Postmenopause


19. Boonananwong S, Kongkathip B, Kongkathip N: First synthesis of 3,16,20-polyoxygenated cholestanes, new cytotoxic steroids from the gorgonian Leptogorgia sarmentosa. Steroids; 2008 Oct;73(11):1123-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antitumor activity against three tumor cell lines (breast cancer, MCF7, lung cancer NCI and oral cancer KB) was evaluated.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Animals. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Small Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cell Line, Tumor. Drug Evaluation, Preclinical. Humans. Inhibitory Concentration 50. Lung Neoplasms / drug therapy. Molecular Structure. Mouth Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550136.001).
  • [ISSN] 0039-128X
  • [Journal-full-title] Steroids
  • [ISO-abbreviation] Steroids
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cholestanes; 0 / Cytotoxins; 0 / Steroids
  •  go-up   go-down


20. Schoppmeyer K, Kreth F, Wiedmann M, Mössner J, Preiss R, Caca K: A pilot study of bendamustine in advanced bile duct cancer. Anticancer Drugs; 2007 Jul;18(6):697-702
Hazardous Substances Data Bank. Bendamustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients with histologically proven, unresectable adenocarcinoma of the hilar bile duct were treated with bendamustine 140 mg/m intravenously on day 1 of the first cycle and with bendamustine 100 mg/m on days 1 and 2 of the second to fourth cycle.
  • Treatment cycles were repeated every 21 days.
  • Primary endpoint was the safety and tolerability of the treatment; secondary endpoints were response rate, time to progression and overall survival.
  • The most common nonhematologic toxicity was mouth dryness grade 2 in six patients.
  • Median time to progression was 3.3 months; median overall survival was 6 months.
  • A potential role of bendamustine in combination therapies for bile duct cancer will be a subject of further trials.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents. Bile Duct Neoplasms / drug therapy. Nitrogen Mustard Compounds
  • [MeSH-minor] Aged. Bendamustine Hydrochloride. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Liver Function Tests. Male. Metabolic Detoxication, Phase II. Middle Aged. Neoplasm Staging. Pilot Projects

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762399.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride
  •  go-up   go-down


21. Murakami J, Lee YJ, Kokeguchi S, Tsujigiwa H, Asaumi J, Nagatsuka H, Fukui K, Kuroda M, Tanaka N, Matsubara N: Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol Rep; 2007 Jun;17(6):1461-7
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines.
  • We have previously shown that the colorectal cancer patients treated with 5-fluorouracil (5-FU) as adjuvant chemotherapy had a better prognosis when the tumor revealed hypermethylation in its MGMT promoter.
  • Therefore, we sought to investigate the relationship between the expression levels of MGMT and the anti-tumor effect of 5-FU in vitro by using two colon adenocarcinoma and four oral cancer cell lines with a variety of MGMT expression.
  • The 5-FU treatment uniformly depleted protein and mRNA expression of MGMT in all cell lines examined.
  • The 5-FU treatment exhibited a better antiproliferative effect on the cells expressing high levels of MGMT by the pretreatment of O6-BG.
  • Assessment of the levels of MGMT expression in cancer cells and the control of its expression could contribute to the effective chemotherapy by 5-FU especially in patients who previously were considered as low-responsive individuals whose tumors have high levels of MGMT.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Colonic Neoplasms / enzymology. Enzyme Inhibitors / pharmacology. Fluorouracil / pharmacology. Guanine / analogs & derivatives. Mouth Neoplasms / enzymology. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Drug Resistance, Neoplasm / drug effects. Humans

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487405.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B: Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology; 2004 Feb;63(2):259-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An open-label pilot study was conducted for 6 months in which the patients took capsules containing the genistein-rich extract three times daily by mouth.
  • The subjects were in one of five groups: after radical retropubic prostatectomy (n = 9), after radiotherapy (n = 17), after both radical retropubic prostatectomy and radiotherapy (n = 6), off-cycle during hormonal therapy (intermittent hormones; n = 14), or active surveillance (n = 16).
  • The primary endpoint for the trial was a 50% reduction in the PSA level at 6 months compared with before treatment.
  • All 8 patients with lower PSA levels at 6 months were in the active surveillance (watchful waiting) treatment subgroup.
  • CONCLUSIONS: A genistein-rich extract as the sole treatment for CaP did not reduce PSA levels by 50% or more in 51 of 52 subjects.
  • Thus, it does not appear to be an effective treatment for CaP when given alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Biomarkers, Tumor / blood. Enzyme Inhibitors / therapeutic use. Genistein / therapeutic use. Neoplasm Proteins / blood. Phytotherapy. Plant Extracts / therapeutic use. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Soybeans / chemistry
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Combined Modality Therapy. Disease Progression. Drugs, Chinese Herbal / therapeutic use. Follow-Up Studies. Humans. Male. Middle Aged. Pilot Projects. Prostatectomy. Protein-Tyrosine Kinases / antagonists & inhibitors. Reishi / chemistry. Testosterone / blood. Treatment Failure


23. Kleikamp S, Böhm M, Frosch P, Brinkmeier T: [Acanthosis nigricans, papillomatosis mucosae and "tripe palms" in a patient with metastasized gastric carcinoma]. Dtsch Med Wochenschr; 2006 May 26;131(21):1209-13
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Acanthosis nigricans, Papillomatosis mucosae und "tripe palms" bei einem Patienten mit metastasiertem Magenkarzinom.
  • HISTORY AND CLINICAL FINDINGS: A 48-year-old obese man presented with thickening, coarseness and hyperpigmentation of the skin, especially of the intertriginous areas, papillomatous to verrucous lesions of the lips and buccal oral mucosa, and hyperkeratosis of the palms ("tripe palms") and soles.
  • Gastroscopic findings were suspicious of adenocarcinoma of the stomach: it was classified histologically as a signet-ring cell, non-mucinous adenocarcinoma.
  • At the time of diagnosis the tumor had already metastasized to perigastric and peripancreatic lymph nodes with peritoneal carcinosis.
  • TREATMENT AND COURSE: Since a curative resection was impossible a gastrojejunostomy was carried out.
  • After this the patient received several courses of chemotherapy according to different schemes.
  • Serum tumor marker levels and cutaneous signs regressed several times.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / secondary. Skin Diseases / etiology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Acanthosis Nigricans / diagnosis. Acanthosis Nigricans / etiology. Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Fatal Outcome. Humans. Immunohistochemistry. Keratoderma, Palmoplantar / diagnosis. Keratoderma, Palmoplantar / etiology. Lymphatic Metastasis. Male. Middle Aged. Mouth Neoplasms / diagnosis. Mouth Neoplasms / etiology. Obesity / complications. Papilloma / diagnosis. Papilloma / etiology. Peritoneal Neoplasms / secondary. Receptor, Melanocortin, Type 1 / analysis

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721709.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / CA-72-4 antigen; 0 / Carcinoembryonic Antigen; 0 / Receptor, Melanocortin, Type 1
  •  go-up   go-down


24. Mok TS, Lam KC, Lee C, Zhang L, Wong H, Chan AT, Yeo W, Yim AP, Chak K, Zee B: Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. Oncology; 2005;68(4-6):485-92
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.
  • OBJECTIVE: This is a randomized phase II study designed to compare the toxicity profile of a non-platinum-based with a platinum-based regimen in the treatment of advanced non-small cell lung cancer.
  • METHODS: Eighty-nine chemotherapy-naïve patients were randomized either to gemcitabine (1,000 mg/m2, 30-min infusion on days 1, 8 and 15) and oral etoposide (50 mg, days 1-14; GE group) or gemcitabine at the same schedule and cisplatin (75 mg/m2 on day 15; GP group).
  • Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
  • Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Quality of Life. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 S. Karger AG, Basel.
  • (PMID = 16020979.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Momm F, Volegova-Neher NJ, Schulte-Mönting J, Guttenberger R: Different saliva substitutes for treatment of xerostomia following radiotherapy. A prospective crossover study. Strahlenther Onkol; 2005 Apr;181(4):231-6
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different saliva substitutes for treatment of xerostomia following radiotherapy. A prospective crossover study.
  • Xerostomia at baseline and under treatment with each compound was measured with a questionnaire approved in a pilot trial.
  • This will help to find the individually best way to cope with the dry mouth.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Radiotherapy / adverse effects. Saliva, Artificial / therapeutic use. Xerophthalmia / drug therapy. Xerophthalmia / etiology
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / radiography. Choice Behavior. Cross-Over Studies. Female. Humans. Lymphoma / radiotherapy. Male. Middle Aged. Radiotherapy Dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827692.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Saliva, Artificial
  •  go-up   go-down


26. Filov VA, Reztsova VV, Kil'maeva NE, Petukhov DV, Pinchuk BT: [An experimental study of the antitumor properties of olipifat]. Vopr Onkol; 2000;46(3):332-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Olipiphat is an original lignin-based mix developed by special technology.
  • It showed antitumor action against carcinoma of Ehrlich, breast adenocarcinoma Ca 755, melanoma B 16, lung carcinoma of Lewis, lymphosarcoma of Pliss, Walker's carcinoma, sarcoma 45 (tumor growth inhibition by 83-92%, increase in survival by 42-54%) and spontaneous murine tumors (the total of 9 pathologies).
  • The drug was administered by 3-5 injections at 2-3 day intervals.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lignin / analogs & derivatives. Lignin / therapeutic use. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Benzopyrenes. Carcinoma, Squamous Cell. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Humans. Mice. Mice, Inbred Strains. Mouth Neoplasms. Neoplasm Transplantation. Rats. Time Factors. Tumor Cells, Cultured / drug effects. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976281.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] RUSSIA
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzopyrenes; 0 / olipifat; 9005-53-2 / Lignin
  •  go-up   go-down


27. Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA: Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum; 2006 Dec;36(3):173-81
MedlinePlus Health Information. consumer health - Scleroderma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The keywords "systemic sclerosis," "esophageal involvement," "gastroesophageal reflux," "esophagitis," and "treatment" were used.
  • Common esophageal manifestations in SSc include motility abnormalities and gastroesophageal reflux (GER), Barrett's esophagus, adenocarcinoma, infectious esophagitis, and drug-induced esophagitis.
  • Extraesophageal manifestations of GER include mouth ulcers, chronic cough, hoarse voice, sore throat, pharyngitis, laryngospasm, asthma, and recurrent pneumonia.
  • Treatment of GER in SSc includes behavioral modification and medical therapy, mainly with proton pump inhibitors.
  • Appropriate treatment of esophageal involvement ameliorates symptoms and prevents complications.

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • Genetic Alliance. consumer health - Scleroderma.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045629.001).
  • [ISSN] 0049-0172
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 111
  •  go-up   go-down


28. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol; 2006 Jan 1;24(1):25-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
  • PURPOSE: To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies.
  • At this dose, the main adverse effects were sore mouth, edema, and thrombocytopenia.
  • Six objective responses were observed in three renal cell carcinomas, one neuroendocrine tumor, one stromal tumor, and one unknown primary adenocarcinoma patient.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Indoles / adverse effects. Indoles / pharmacokinetics. Neoplasms / drug therapy. Pyrroles / adverse effects. Pyrroles / pharmacokinetics. Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Area Under Curve. Female. Humans. Hypertension / chemically induced. Male. Middle Aged. Pigmentation / drug effects. Skin / drug effects


29. Scheinfeld N, Rosenberg JD, Weinberg JM: Levamisole in dermatology : a review. Am J Clin Dermatol; 2004;5(2):97-104
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Levamisole, an anthelmintic agent with a wide range of immunomodulatory actions, has been used successfully as monotherapy and an adjunct to treatment in a variety of diseases.
  • Since 1990, combination therapy of levamisole and fluorouracil has played an important role in the treatment of resected Dukes stage C adenocarcinoma of the colon.
  • In dermatologic disease levamisole has been successfully used in the treatment of parasitic, viral and bacterial infections including leprosy, collagen vascular diseases, inflammatory skin diseases and children with impaired immune a variety of reasons.
  • It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Levamisole / therapeutic use. Skin Diseases / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15109274.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 2880D3468G / Levamisole
  • [Number-of-references] 124
  •  go-up   go-down


30. Adamsson I, Edlund C, Nord CE: Microbial ecology and treatment of Helicobacter pylori infections: review. J Chemother; 2000 Feb;12(1):5-16
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbial ecology and treatment of Helicobacter pylori infections: review.
  • Treatment regimens included in the study were omeprazole alone (OP), in combination with amoxicillin (OA), in combination with amoxicillin and metronidazole (OAM) and in combination with clarithromycin and metronidazole (OCM).
  • Samples from the mouth (saliva and dental plaque), stomach (biopsies from the gastric mucosa in the corpus and in the antrum) and the intestine (feces) were collected before, during and after treatment.
  • The oral microflora was challenged by the three treatment regimens including antimicrobial agents, with the emergence of resistant streptococci and staphylococci in the OCM group.
  • Bacterial strains in the gastric mucosa increased in numbers during treatment in all treatment groups, probably due to the pH rise, which provides a better environment for the commensal microflora.
  • This overgrowth was especially pronounced during treatment with omeprazole alone (OP), possibly due to the fact that a concomitant suppression exerted by the antimicrobial agents occurred in the other treatment groups. H. pylori was, on the other hand, suppressed during treatment in all treatment groups, possibly due to a direct effect of omeprazole and to the colonization resistance expressed by the normal microflora.
  • The intestinal microflora was most altered in the OAM and the OCM groups, with persistent disturbances in the OCM group 4 weeks after treatment.
  • The frequency of resistant Enterococcus spp. (OCM), Enterobacteriaceae spp. (OA and OAM) and Bacteroides spp. (OCM) was increased during and after treatment.
  • Different detection methods for H. pylori were compared and PCR was shown to have higher sensitivity than other routine diagnostic tests.
  • Treatment failures in patients treated with OAM were caused by recrudescence.
  • These four patients with relapsing H. pylori infection, were shown to be reinfected with the original H. pylori strain, indicating that H. pylori escapes treatment by a thus far unknown mechanism.
  • [MeSH-major] Anti-Bacterial Agents / pharmacology. Anti-Ulcer Agents / pharmacology. Genetic Variation. Helicobacter Infections / drug therapy. Helicobacter pylori / pathogenicity
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / microbiology. Adult. Aged. Amoxicillin / adverse effects. Amoxicillin / pharmacology. Clarithromycin / adverse effects. Clarithromycin / pharmacology. Drug Resistance, Microbial. Female. Gastric Mucosa / drug effects. Gastric Mucosa / microbiology. Gastritis / drug therapy. Gastritis / microbiology. Humans. Hydrogen-Ion Concentration. Male. Metronidazole / adverse effects. Metronidazole / pharmacology. Middle Aged. Omeprazole / adverse effects. Omeprazole / pharmacology. Penicillins / adverse effects. Penicillins / pharmacology. Peptic Ulcer / drug therapy. Peptic Ulcer / microbiology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10768510.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 0 / Penicillins; 140QMO216E / Metronidazole; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole
  • [Number-of-references] 55
  •  go-up   go-down


31. Jin J, Li YX, Wang JW, Wang WH, Liu YP, Wang K, Fang H, Zhou ZX, Zhou AP, Yu ZH: Phase I study of oxaliplatin in combination with capecitabine and radiotherapy as postoperative treatment for stage II and III rectal cancer. Int J Radiat Oncol Biol Phys; 2008 Nov 1;72(3):671-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of oxaliplatin in combination with capecitabine and radiotherapy as postoperative treatment for stage II and III rectal cancer.
  • PURPOSE: A Phase I study was conducted to determine the maximal tolerated dose and the dose-limiting toxicity (DLT) of oxaliplatin (OXA) combined with capecitabine and radiotherapy as adjuvant treatment in patients with operable rectal cancer.
  • PATIENTS AND METHODS: A total of 21 patients with Stage II or III rectal adenocarcinoma after curative surgery were treated with radiotherapy to a total dose of 50 Gy in 5 weeks.
  • CONCLUSIONS: OXA combined with a fixed dose of capecitabine at 625 mg/m(2) twice daily by mouth plus radiotherapy in the adjuvant setting was tolerable and clinically feasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Organoplatinum Compounds / toxicity. Pyridines / toxicity. Radiotherapy / methods. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Capecitabine. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455328.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Pyridines; 0 / oxiplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Hausner SH, Abbey CK, Bold RJ, Gagnon MK, Marik J, Marshall JF, Stanecki CE, Sutcliffe JL: Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res; 2009 Jul 15;69(14):5843-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cell surface receptor alpha(v)beta(6) is epithelial specific, and its expression is tightly regulated; it is low or undetectable in adult tissues but has been shown to be increased in many different cancers, including pancreatic, cervical, lung, and colon cancers.
  • We have recently shown the feasibility of imaging alpha(v)beta(6) in vivo by positron emission tomography (PET) using the peptide [(18)F]FBA-A20FMDV2.
  • Pancreatic ductal adenocarcinoma is highly metastatic and current preoperative evaluation of resectability using noninvasive imaging has limited success, with most patients having metastases at time of surgery.
  • The fact that these tumors express alpha(v)beta(6) suggests that this probe has significant potential for the in vivo detection of this malignancy, thus having important implications for patient care and therapy.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] J Oral Pathol Med. 2006 Jan;35(1):1-10 [16393247.001]
  • [Cites] Mol Pharm. 2006 Sep-Oct;3(5):472-87 [17009846.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:4S-18S [17204716.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S [17204723.001]
  • [Cites] Radiology. 2007 Feb;242(2):360-85 [17255408.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] J Pathol. 2007 Jul;212(3):316-24 [17503414.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5889-95 [17575158.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7833-40 [17699789.001]
  • [Cites] Cancer Invest. 2007 Oct;25(7):632-46 [18027153.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):561-70 [18199553.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 Feb;20(1):61-6 [17981018.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1271-86 [18385522.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(4):429-35 [18670846.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6351-3 [18927272.001]
  • [Cites] J Nucl Med. 2000 Mar;41(3):429-38 [10716315.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):641-50 [11340566.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Feb 10;55(2):217-50 [12564978.001]
  • [Cites] Nat Rev Drug Discov. 2003 Mar;2(3):214-21 [12612647.001]
  • [Cites] Nat Rev Drug Discov. 2003 May;2(5):347-60 [12750738.001]
  • [Cites] Semin Nucl Med. 2004 Jan;34(1):56-69 [14735459.001]
  • [Cites] Histopathology. 2004 Sep;45(3):226-36 [15330800.001]
  • [Cites] J Biol Chem. 1990 Jul 15;265(20):11502-7 [2365683.001]
  • [Cites] Radiology. 1993 Dec;189(3):847-50 [8234714.001]
  • [Cites] J Histochem Cytochem. 1993 Oct;41(10):1521-7 [8245410.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2241-51 [7673344.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1565-70 [9843289.001]
  • [Cites] Ann Surg. 1999 May;229(5):729-37; discussion 737-8 [10235532.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):339-47 [15668738.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(1):4-10 [15747028.001]
  • [Cites] Cancer Metastasis Rev. 2005 Sep;24(3):395-402 [16258727.001]
  • (PMID = 19549907.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA107792-02; United States / NCI NIH HHS / CA / R21 CA107792; United States / NCI NIH HHS / CA / R21 CA107792-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Benzoates; 0 / Fluorine Radioisotopes; 0 / Integrins; 0 / Radiopharmaceuticals; 0 / Viral Proteins; 0 / integrin alphavbeta6; V5ROO2HOU4 / 4-fluorobenzoic acid
  • [Other-IDs] NLM/ NIHMS117292; NLM/ PMC2711989
  •  go-up   go-down


33. Ngeow JY, Prakash KM, Chowbay B, Quek ST, Choo SP: Capecitabine-induced oromandibular dystonia: a case report and literature review. Acta Oncol; 2008;47(6):1161-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Stem / drug effects. Deoxycytidine / analogs & derivatives. Dystonia / chemically induced. Fluorouracil / analogs & derivatives. Mandible / drug effects. Mouth / drug effects
  • [MeSH-minor] Adenocarcinoma / drug therapy. Asian Continental Ancestry Group. Capecitabine. Drug Administration Schedule. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Dystonia.
  • MedlinePlus Health Information. consumer health - Dystonia.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for oromandibular dystonia .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607849.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Number-of-references] 16
  •  go-up   go-down






Advertisement